STAT3 and hepatocellular carcinoma: To determine whether combined inhibition of the Notch and JAK/STAT pathways could mimic the effects of HepLPCs, HCC cells were treated with 10 μM DAPT and 10 μM ruxolitinib (Ruxo) to inhibit the Notch1 and STAT3 signaling pathways, respectively.